KRAS and cancer: Patients with cancers with mutations in RAS (HRAS, KRAS, and NRAS) had an overall response rate of 31% compared to a response rate of 32% in patients with RET-mutation positive disease with no survival benefit observed in patients with tumors lacking both RET and RAS mutations (54).